Fosaprepitant


Fosaprepitant, Ivemend ) is an antiemetic drug, administered intravenously. It is a prodrug of aprepitant.
Fosaprepitant was developed by Merck & Co. and was approved by the United States Food and Drug Administration on January 25, 2008 and by the European Medicines Agency on January 11 of the same year.